Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT04945421
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM Patients
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT04940546
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adjuvant Chemotherapy and Anti-PD-1 Antibody in Patients With Stage IIIC2-IVB Cervical Cancer
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2021-06-09
- Lead Sponsor
- Taizhou Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT04918628
- Locations
- 🇨🇳
Youyou Xie, Taizhou, Zhejiang, China
Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 46
- Registration Number
- NCT04906044
- Locations
- 🇨🇳
First Hospital of Jilin University, Changchun, Jilin, China
Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT04899427
- Locations
- 🇨🇳
Wei Zhang, Beijing, Beijing, China
Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-05-12
- Target Recruit Count
- 100
- Registration Number
- NCT04882462
The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Guangdong Provincial People's Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04877821
- Locations
- 🇨🇳
NeoSACT, Guangzhou, Guangdong, China
IBI188 Combination Therapy in Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2022-10-04
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 9
- Registration Number
- NCT04861948
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
- First Posted Date
- 2021-04-14
- Last Posted Date
- 2021-04-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04843943
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT04842565
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath